AC Immune Reports Q1 2025 Results, Advances Neurodegenerative Disease Portfolio

• AC Immune reports Q1 2025 financial results • Cash resources: CHF 145.7 million as of March 31, 2025 • Funding until Q1 2027 before potential milestones • Positive interim results for ACI-7104.056 in PD Phase 2 trial • Immunogenicity and good safety observed • Additional interim results expected in Q2 2025 • Presentations at AD/PD 2025 highlight active immunotherapy leadership • Promising data on early-stage assets

Lausanne, Switzerland, April 30, 2025 — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, has released its Q1 2025 financial results. The company reported a solid cash position of CHF 145.7 million as of March 31, 2025, providing funding into Q1 2027 [1].

Key highlights of the quarter include positive interim Phase 2 results for ACI-7104.056, an anti-alpha-synuclein immunotherapy for Parkinson's disease. The treatment induced anti-a-syn antibodies over 20-fold higher than placebo levels after four immunizations, demonstrating strong immunogenicity and favorable safety [1].

The company's research and development (R&D) expenses increased to CHF 15.9 million from CHF 15.2 million in Q1 2024, while general and administrative (G&A) expenses decreased to CHF 4.4 million from CHF 5.0 million. The net loss widened to CHF 19.0 million compared to CHF 17.9 million in the same period last year, reflecting increased investment in clinical programs [1].

AC Immune's pipeline is bolstered by multiple clinical-stage candidates, including two additional Phase 2 active immunotherapy programs (ACI-24.060 and ACI-35.030) advancing in Alzheimer's disease trials. Early-stage assets highlighted at the AD/PD™ 2025 conference, such as Morphomer® small molecules targeting alpha-synuclein and tau, and a novel Morphomer®-antibody drug conjugate platform, further enhance the company's portfolio [1].

The company expects several value-inflection points throughout 2025, including interim data from the ACI-7104.056 Phase 2 program in Parkinson's disease (Q2 2025) and potential initiation of Part 2 of the VacSYn trial (H2 2025). Promising immunogenicity data for AC Immune's Parkinson's immunotherapy shows a 20-fold antibody increase, with efficacy biomarker data pending in Q2 2025 [1].

AC Immune's active immunotherapy approach for neurodegenerative diseases represents a differentiated strategy focusing on precision prevention rather than symptom management. The company's financial structure supports multiple value-inflection opportunities throughout 2025, including interim data from the ACI-7104.056 Phase 2 program in Parkinson's disease (Q2 2025) and potential initiation of Part 2 of the VacSYn trial (H2 2025) [1].

References:
[1] https://www.stocktitan.net/news/ACIU/ac-immune-reports-first-quarter-2025-financial-results-and-provides-zxra7k1l2hz3.html